DNA Sequencing Market Summary
As per Market Research Future Analysis, the DNA Sequencing Market was valued at USD 13.46 billion in 2023 and is projected to reach USD 46.85 billion by 2032, growing at a CAGR of 12.97% from 2024 to 2032. Key drivers include advancements in sequencing technology, increased applications in personalized medicine, and rising demand for genomic research. The market is segmented into consumables, instruments, and services, with consumables holding the largest share. Applications span diagnostics, oncology, and forensics, with significant growth expected in personalized medicine. North America leads the market, followed by Europe and Asia-Pacific, with notable investments in R&D and technological advancements fueling growth.
Key Market Trends & Highlights
The DNA Sequencing Market is witnessing significant growth driven by technological advancements and increased applications.
- Market Size in 2023: USD 13.46 billion; projected to reach USD 46.85 billion by 2032.
- CAGR of 12.97% during the forecast period (2024-2032).
- North America accounted for USD 1.05 billion in 2022, leading the market share.
- Biomarkers & cancer applications hold a considerable market share, driven by rising cancer prevalence.
Market Size & Forecast
2023 Market Size: USD 13.46 billion
2024 Market Size: USD 15.63 billion
2032 Market Size: USD 46.85 billion
CAGR: 12.97% (2024-2032)
Largest Regional Market: North America.
Major Players
Key players include Illumina, Inc., Roche, Thermo Fisher Scientific, QIAGEN, and Pacific Biosciences.
DNA Sequencing Market Trends
- Increased technological advancement to boost the market growth
DNA sequencing technology can sequence multiple DNA strands through massive parallelization. Such sequencing includes Sanger sequencing and non-Sanger sequencing. Compared with microarrays and other genomic analysis methods, DNA sequencing has the advantages of low cost, high accuracy, high speed, and precise results, even with small sample input volumes. DNA sequencing is used to perform a variety of applications, such as biomarker discovery, oncology research, personalized medicine, forensics, and more. It simplifies nucleotide analysis and is a broad alternative to traditional genomics tools, notably microarrays, genotyping, and more.
The demand for DNA sequencing has increased significantly owing to the proliferation of sequencing applications and the increase in technological advancements in DNA sequencing. Moreover, the surge in genome mapping initiatives and increasing investment in research and development across the globe drive market growth.
DNA sequencing has brought about a paradigm shift in proteomics and genomics research. It is a highly accurate and high-throughput technology used in various applications such as de novo assembly, WGS, and DNA resequencing. Therefore, the technology is quickly adopted by several academic research institutions for research. Illumina installed the NovaSeq 6000 Sequencing System at the Whitehead Biomedical Research Institute in Massachusetts, USA, in June 2020.
The market of DNA sequencing is driven by efforts by the Centers for Medicare & Medicaid Services (CMS), the Society for Molecular Pathology, and commercial payers such as Blue Cross Blue Shield and Aetna to facilitate the clinical use of sequencing technology. For example, in January 2020, China Medical System expanded the coverage of NGS-based diagnostic tests for ovarian and breast cancer patients, providing patients with more opportunities for personalized cancer care. Therefore, the market CAGR of DNA Sequencing has been increasing globally in recent years. These are essential factors driving the DNA Sequencing market revenue growth.
Â
The sequencing of DNA is a method that uses extensive parallelization to sequence many DNA strands. Both Sanger's technique and non-Sanger methods of sequencing are used in this sequencing. The development of pharmacological treatments for cancer is accelerated by individualized targeted sequencing of tumors, which also discovers cancer targets or pathways. Introducing large-scale initiatives utilizing NGS techniques produces a fresh fundamental understanding of oncology precision therapy. Compared to microarray and other genetic analysis methods, DNA sequencing offers advantages such as excellent accuracy & speed, cheap cost, and accurate results even with limited sample input.
Biomarker identification, forensic analysis, oncology research, and individualized healthcare are among the uses for DNA sequencing.
It has greatly outperformed more traditional genomics methods, including genotyping, microarray, and others, and has sped up the study of nucleotides. DNA sequencing, a highly accurate and high-throughput technology utilized for various applications, including WGS, de novo assembly, and DNA resequencing, has caused an upheaval in proteomic and genomic studies. As a result, several academic research institutions can utilize this technology for research investigations. Consumer call for DNA sequencing has significantly increased due to the surge in sequencing applications and growth in DNA sequencing technology. Additionally, a boost in worldwide genome mapping efforts and R&D spending drive the market's expansion.
Technology advancements in DNA sequencing, increased clinical diagnostics and drug development applications, and higher R&D spending influence market growth. Applications for DNA sequencing can be found in forensics, personalized medicine, biomarkers, reproductive health, and other fields. DNA sequencing technology has enormous potential in clinical research and development for cancer diagnostics and therapies. The ability of NGS, or next-generation sequencing, to find and characterize clinically relevant genetic variations across several genes in a single test has recently been established quickly and affordably.
In June 2024: Roche announced a strategic partnership with a leading bioinformatics company to enhance DNA sequencing data analysis capabilities.
In November 2023, Illumina, Inc. unveiled its Global Health Access Initiative to improve the access to sequencing tools used in public health by poor nations. PacBio has entered into an agreement to acquire Apton Biosystems by August 2023. The takeover is expected to fasten short-read sequencer development, prompting the market growth
DNA Sequencing Market Segment Insights
DNA Sequencing Product Insights
Based on Product, the market segments of DNA Sequencing includes Consumables, Instruments, and Service. The consumable segment held the majority share in 2022, contributing most of the DNA Sequencing market revenue. The wide availability of reagents and kits for all library construction steps, such as DNA fragmentation, enrichment, adapter ligation, amplification, and quality control, contributes to a larger share of this segment. Most of these tools feature streamlined and simplified workflows, ready-to-use components, and compatibility with low-input and formalin-fixed specimens.
The continuous availability and availability of reagents and kits have made WGS more accessible and affordable, driving the market of DNA sequencing.
DNA Sequencing Application Insights
Application has bifurcated the DNA Sequencing market data into diagnostics, biomarkers & cancer, reproductive health, personalized medicine, and forensics. Biomarkers & cancer have a considerable share of the market. The market is expected to grow over the forecast year owing to the increasing prevalence of cancer and advancements in next-generation sequencing technologies. However, the personalized medicine segment is expected to witness considerable growth in the next-generation sequencing market over the forecast period owing to surging demand for drug treatments, advancements in research and development in healthcare, and rising awareness of NGS testing in the pharmaceutical and biotechnology industries.
DNA Sequencing Technology Insights
The DNA Sequencing market segmentation has been divided based on Technology into Semiconductor Sequencing, Sequencing by Ligation, and Pyrosequencing. Sequencing by ligation accounted for the largest market share of the DNA Sequencing due to the widespread use of DNA sequencing platforms in sequencing scenarios. It is likely to continue to dominate throughout the forecast period.
DNA Sequencing End-User Insights
Based on End-User, the DNA Sequencing industry has been segmented into academic & government research institutes, pharmaceutical companies, biotechnology companies, and hospitals & clinics. The academic & government research institute segment is expected to contribute a higher market share due to the wide acceptance of Sanger techniques and NGS in academic and institutional research projects. Moreover, rising funding and investment plans increase these entities' demand for DNA sequencing products, leading to a more significant revenue share.
Figure 1 DNA Sequencing Market by End-User, 2022 & 2030 (USD billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
News: The most current findings come from the prospective research GEMINI, or Genomic Medicine in Ill Infants and Newborns, in which four hundred hospitalized newborns had their complete genomes sequenced and underwent targeted gene panel testing. Even though it took longer, whole-genome sequencing beat the targeted test at identifying the origin of an infant's symptoms, with a diagnosis rate of 49% as opposed to 27% for the smaller panel. One-fifth of the individuals saw modifications to their treatment, such as medical professionals choosing to use or forgo specific medications and surgical treatments.
DNA Sequencing Regional Insights
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. North American DNA Sequencing market, which accounted for USD 1.05 billion in 2022, is expected to exhibit a significant CAGR growth during the study period. Continuous technological development by major players, high investment in R&D, and availability of technologically advanced healthcare infrastructure have led North America to hold a leading market share in the DNA sequencing. Several government initiatives in the United States and Canada support drug development and cancer treatment research.
Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 DNA SEQUENCING MARKET SHARE BY REGION 2023 (%)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's DNA Sequencing market accounts for the second-largest market share. Increasing adoption of organic growth strategies, such as product launches by key players in the Region to expand product portfolios, is expected to drive market growth over the forecast period. For example, in December 2021, Swiss-based pharmaceutical company F. Hoffmann-La Roche Ltd announced the launch of the AVENIO Edge System to provide a fully automated, integrated sequencing solution. The AVENIO Edge System is a pre-analytical platform for sequencing library preparation, target enrichment, and quantification steps that provides integrated end-to-end control and reliable, consistently high-quality results.
Further, the German market of DNA Sequencing held the largest market share, and the U.K. market of DNA Sequencing was the fastest-growing market in the European Region.
The Asia-Pacific DNA Sequencing Market is expected to grow at the fastest CAGR from 2024 to 2032. A growing customer base drives international companies to expand their business through strategic moves. A prominent California company has raised over $75 million to expand its desktop DNA sequencers to support the ongoing crisis of COVID-19. Moreover, the China market of DNA Sequencing held the largest market share, and the Indian market of DNA Sequencing was the fastest-growing market in the Asia-Pacific region.
DNA Sequencing Key Market Players & Competitive Insights
Major market players are spending a lot on R&D to increase their product lines, which will help the market of DNA Sequencing grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the DNA Sequencing industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the DNA Sequencing industry to benefit clients and expand the market sector. The DNA Sequencing industry has provided medicine with some of the most significant benefits in recent years. In the market of DNA Sequencing, major players such as Abbott Laboratories, Terumo Corporation, Cardinal Health Inc., Cardiva Medical Inc., Morris Innovative Inc., and others are working on expanding the market demand by investing in research and development activities.
Illumina, Inc. is an American biotechnology company headquartered in San Diego, California, serving over 140 countries. Illumina was founded on April 1, 1998, to develop, manufacture, and sell integrated systems to analyze genetic variation and biological function. The company offers a range of products and services for sequencing, genotyping, gene expression, and proteomics. On January 9, 2023, pharmaceutical company Illumina Inc. and Nashville Biosciences LLC, a wholly owned Vanderbilt University Medical Center (VUMC) subsidiary, announced an agreement with biopharmaceutical company Amgen to sequence the whole genome of DNA samples of approximately 35,000 samples.
The protocol helps accelerate therapeutic development through genomics and builds superior clinical genomic datasets.
Also, F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company with two divisions Pharmaceuticals and Diagnostics. The shares of its holding company, Roche Holding AG, are listed on the six major Swiss exchanges. The company is headquartered in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the world's leading provider of cancer treatments. In May 2020, F. Hoffman-La Roche Ltd. announced the acquisition of Stratos Genomics to advance the development of Roche nanopore sequencers. Roche believes the acquisition helps address clinical research needs and, thus, patient needs.
Key Companies in the DNA Sequencing market include
- Thermo Fisher Scientific Inc.
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences of California Inc.
Dna Sequencing Market Industry Developments
-
Q2 2024: Illumina to spin off Grail after antitrust pressure Illumina announced it will divest cancer detection company Grail following a lengthy antitrust battle with U.S. and European regulators, marking a major shift in the DNA sequencing sector.
-
Q2 2024: PacBio Launches Revio 2.0, a New High-Throughput Sequencing System Pacific Biosciences (PacBio) unveiled the Revio 2.0, a next-generation sequencing platform designed to deliver higher throughput and lower costs for whole-genome sequencing applications.
-
Q2 2024: Oxford Nanopore Technologies and NVIDIA Announce Strategic Partnership for AI-Driven Genomics Oxford Nanopore Technologies entered a partnership with NVIDIA to integrate AI-powered analytics into its DNA sequencing platforms, aiming to accelerate genomic data interpretation.
-
Q1 2024: Element Biosciences Raises $277 Million in Series C Funding Element Biosciences, a developer of DNA sequencing technology, secured $277 million in Series C funding to expand commercialization of its AVITI sequencing platform.
-
Q2 2024: Thermo Fisher Scientific Receives FDA Clearance for Next-Generation Sequencing-Based Test Thermo Fisher Scientific announced FDA clearance for its Oncomine Dx Express Test, a next-generation sequencing assay for solid tumor profiling in cancer diagnostics.
-
Q1 2024: Roche Acquires Stratos Genomics to Advance DNA Sequencing Technology Roche completed the acquisition of Stratos Genomics, a company specializing in nanopore-based sequencing, to enhance its portfolio of next-generation sequencing solutions.
-
Q2 2024: Illumina Appoints Jacob Thaysen as Chief Executive Officer Illumina announced the appointment of Jacob Thaysen as its new CEO, signaling a leadership change at the DNA sequencing giant.
-
Q1 2024: Ultima Genomics Raises $100 Million to Scale Ultra-Low-Cost Sequencing Platform Ultima Genomics raised $100 million in new funding to accelerate the commercialization of its high-throughput, low-cost DNA sequencing technology.
-
Q2 2024: BGI Genomics Opens New Sequencing Facility in Singapore BGI Genomics inaugurated a new high-capacity DNA sequencing facility in Singapore to serve the Asia-Pacific region and expand its global footprint.
-
Q1 2024: Singular Genomics Systems Announces Initial Public Offering Singular Genomics Systems filed for an IPO on the NASDAQ, aiming to raise capital for the development and commercialization of its next-generation sequencing platforms.
-
Q2 2024: Qiagen and BioNTech Announce Collaboration on Personalized Cancer Sequencing Qiagen and BioNTech entered a strategic collaboration to develop and commercialize next-generation sequencing solutions for personalized cancer immunotherapy.
-
Q1 2024: Agilent Technologies Launches New Target Enrichment Solution for NGS Agilent Technologies introduced a new SureSelect target enrichment product designed to improve the efficiency and accuracy of next-generation DNA sequencing workflows.
DNA Sequencing Market Segmentation
DNA Sequencing Product Outlook
DNA Sequencing Application Outlook
DNA Sequencing Technology Outlook
DNA Sequencing End-User Outlook
- Academic & Government Research Institutes
DNA Sequencing Regional Outlook
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 13.46 billion |
| Market Size 2024 |
USD 15.63billion |
| Market Size 2032 |
USD 46.85 billion |
| Compound Annual Growth Rate (CAGR) |
12.97% (2024-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2019 - 2021 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Product, Application, Technology, End-User, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered |
The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Agilent Technologies Inc., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Oxford Nanopore Technologies Ltd., Macrogen Inc., Perkin Elmer Inc., Pacific Biosciences of California Inc., BGI. |
| Key Market Opportunities |
New product launches and R&D Amongst major key Players. |
| Key Market Dynamics |
Growing requirement of breeders for animals and plant production Development in technology It is increasing research and development. |
Frequently Asked Questions (FAQ):
The DNA sequencing market size was valued at USD 13.46 Billion in 2023.
The market is projected to grow at a CAGR of 12.97% during the forecast period, 2024-2032.
North America had the largest share of the market.
The key players in the market are Agilent Technologies Inc., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, and F. Hoffmann-La Roche Ltd.
The consumable DNA sequencing category dominated the market in 2023.
Biomarkers & cancer had the largest share of the market.
Table of Contents:
Chapter 1. DNA Sequencing System Market Report Prologue
Chapter 2. DNA Sequencing System Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. DNA Sequencing System Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. DNA Sequencing System Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global DNA Sequencing System Market, by Type
6.1 Introduction
6.2 Instruments and Consumables
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.3 Services
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.4 Workflow Products
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 7. Global DNA Sequencing System Market, by Product
7.1 Introduction
7.2 Systematic Antibiotics
7.3 Sequencing services
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4 Sequencing instruments and consumables
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4.1 Sequencing instruments and consumables by product type
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4.1.1 Consumables
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4.1.2 Instruments
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4.2 Sequencing instruments and consumables by platform
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4.2.1 NGS
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4.2.2 Sanger
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4.2.3 Bioinformatics
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4.2.4 Sample prep kits and reagents
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 8. Global DNA Sequencing System Market, by Technology
8.1 Introduction
8.2 Semiconductor sequencing
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.3 Pyrosequencing
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.4 Sequencing by synthesis
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.5 Single-molecule real-time sequencing (SMRT)
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.6 Sequencing by ligation (SBL)
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.7 Other technologies
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 9. Global DNA Sequencing System Market, by Application
9.1 Introduction
9.2 Diagnostics
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
9.3 Agriculture & animal research
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
9.4 Biomarker discovery
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
9.5 Personalized medicine
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
9.6 Drug discovery
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
9.7 Other applications
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 10. Global DNA Sequencing System Market, by End-Users
10.1 Introduction
10.2 Research centres and government institutes & academia
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
10.3 Biotechnology & Pharmaceutical companies
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
10.4 Clinics & Hospitals
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
10.5 Other end-users
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 11. Global DNA Sequencing System Market, by Region
11.1 Introduction
11.2 America
11.2.1 North America
11.2.1.1 US
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 Italy
11.3.1.4 Spain
11.3.1.5 UK
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia-Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 South Korea
11.4.6 Rest of Asia-Pacific
11.5 Middle East & Africa
11.5.1 Middle East
11.5.2 Africa
Chapter 12. DNA Sequencing System Market Company Landscape
12.1 Introduction
12.2 Market Share Analysis
12.3 Key Development & Strategies
Chapter 13. Company Profiles
13.1 Perkin Elmer
13.1.1 Company Overview
13.1.2 Product Overview
13.1.3 Financials Overview
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.2 Roche Holdings AG
13.2.1 Company Overview
13.2.2 Product Overview
13.2.3 Financial Overview
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.3 Siemens AG
13.3.1 Company Overview
13.3.2 Product Overview
13.3.3 Financial Overview
13.3.4 Key Development
13.3.5 SWOT Analysis
13.4 Illumina
13.4.1 Company Overview
13.4.2 Product Overview
13.4.3 Financial Overview
13.4.4 Key Development
13.4.5 SWOT Analysis
13.5 Agilent Technologies Inc
13.5.1 Company Overview
13.5.2 Product Overview
13.5.3 Financial overview
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.6 Genia Corporation
13.6.1 Company Overview
13.6.2 Product Overview
13.6.3 Financial Overview
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.7 Oxford Nanopore technologies
13.7.1 Overview
13.7.2 Product Overview
13.7.3 Financial Overview
13.7.4 Key Developments
13.7.5 SWOT Analysis
13. 8 Koninklijke Philips N.V.
13.8.1 Overview
13.8.2 Product Overview
13.8.3 Financials
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.9 Pacific Biosciences
13.9.1 Overview
13.9.2 Product Overview
13.9.3 Financials
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.10 Johnson & Johnson
13.10.1 Overview
13.10.2 Product Overview
13.10.3 Financials
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.11 Deep Genomics, Inc
13.11.1 Overview
13.11.2 Product Overview
13.11.3 Financials
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.12 Life Technologies
13.12.1 Overview
13.12.2 Product Overview
13.12.3 Financials
13.12.4 Key Developments
13.12.5 SWOT Analysis
13. 13 Eppendorf
13. 13.1Overview
13. 13.2Product Overview
13. 13.3Financials
13. 13.4Key Developments
13. 13.5SWOT Analysis
13. 14 Tecan
13. 14.1Overview
13. 14.2Product Overview
13. 14.3Financials
13. 14.4Key Developments
13. 14.5SWOT Analysis
13. 15 Hamilton Thorne Biosciences
13. 15.1Overview
13. 15.2Product Overview
13. 15.3Financials
13. 15.4Key Developments
13. 15.5SWOT Analysis
13. 16 General Electric Company
13.16.1Overview
13.16.2Product Overview
13.16.3Financials
13.16.4Key Developments
13.16.5SWOT Analysis
13. 17 Siemens Healthineers GmbH
13.17.1Overview
13.17.2Product Overview
13.17.3Financials
13.17.4Key Developments
13.17.5SWOT Analysis
13. 18 Myriad Genetics
13.18.1Overview
13.18.2Product Overview
13.18.3Financials
13.18.4Key Developments
13.18.5SWOT Analysis
13.19 Bayer Corporation
13.19.1Overview
13.19.2Product Overview
13.19.3Financials
13.19.4Key Developments
13.19.5SWOT Analysis
13.20 Beckman Coulter
13.20.1Overview
13.20.2Product Overview
13.20.3Financials
13.20.4Key Developments
13.20.5SWOT Analysis
13.21 Thermo Scientific
13.21.1Overview
13.21.2Product Overview
13.21.3Financials
13.21.4Key Developments
13.21.5SWOT Analysis
Chapter 14 MRFR Conclusion
14.1 Key Findings
14.1.1 From CEO’s Viewpoint
14.1.2 Unmet Needs of the Market
14.2 Key Companies to Watch
14.3 Predictions for the Global DNA Sequencing Industry
Chapter 15. Appendix
LIST OF TABLES
Table 1 Global DNA Sequencing System Market Synopsis, 2023-2030
Table 2 Global DNA Sequencing System Market Estimates and Forecast, 2023-2030 (USD Million)
Table 3 Global DNA Sequencing System Market, by Types, 2023-2030 (USD Million)
Table 4 Global DNA Sequencing System Market, by Product, 2023-2030 (USD Million)
Table 5 Global DNA Sequencing System Market, by Technology, 2023-2030 (USD Million)
Table 6 Global DNA Sequencing System Market, by Application, 2023-2030 (USD Million)
Table 7 Global DNA Sequencing System Market, by End-User, 2023-2030 (USD Million)
Table 8 Global DNA Sequencing System Market, by Region, 2023-2030(USD Million)
Table 9 North America: DNA Sequencing System Market, by Types, 2023-2030 (USD Million)
Table 10 North America: DNA Sequencing System Market, by Product, 2023-2030 (USD Million)
Table 11 North America: DNA Sequencing Market, by Technology, 2023-2030 (USD Million)
Table 12 North America: DNA Sequencing Market, by Application, 2023-2030 (USD Million)
Table 13 North America: DNA Sequencing Market, by End-User, 2023-2030 (USD Million)
Table 14 North America: DNA Sequencing Market, by Region, 2023-2030 (USD Million)
Table 15 US: DNA Sequencing Market, by Types, 2023-2030 (USD Million)
Table 16 US: DNA Sequencing Market, by Product, 2023-2030 (USD Million)
Table 17 US: DNA Sequencing Market, by Technology, 2023-2030 (USD Million)
Table 18 US: DNA Sequencing Market, by Application, 2023-2030 (USD Million)
Table 19 US: DNA Sequencing Market, by End-User, 2023-2030 (USD Million)
Table 20 US: DNA Sequencing Market, by Region, 2023-2030 (USD Million)
Table 21 Canada: DNA Sequencing Market, by Types, 2023-2030 (USD Million)
Table 22 Canada: DNA Sequencing Market, by Product, 2023-2030 (USD Million)
Table 23 Canada: DNA Sequencing Market, by Technology, 2023-2030 (USD Million)
Table 24 Canada: DNA Sequencing Market, by Application, 2023-2030 (USD Million)
Table 25 Canada: DNA Sequencing Market, by End-User, 2023-2030 (USD Million)
Table 26 Canada: DNA Sequencing Market, by Region, 2023-2030 (USD Million)
Table 27 South America: DNA Sequencing Market, by Types, 2023-2030 (USD Million)
Table 28 South America: DNA Sequencing Market, by Product, 2023-2030 (USD Million)
Table 29 South America: DNA Sequencing Market, by Technology, 2023-2030 (USD Million)
Table 30 South America: DNA Sequencing Market, by Application, 2023-2030 (USD Million)
Table 31 South America: DNA Sequencing Market, by End-User, 2023-2030 (USD Million)
Table 32 South America: DNA Sequencing Market, by Region, 2023-2030 (USD Million)
Table 33 Europe: DNA Sequencing Market, by Types, 2023-2030 (USD Million)
Table 34 Europe: DNA Sequencing Market, by Product, 2023-2030 (USD Million)
Table 35 Europe: DNA Sequencing Market, by Technology, 2023-2030 (USD Million)
Table 36 Europe: DNA Sequencing Market, by Application, 2023-2030 (USD Million)
Table 37 Europe: DNA Sequencing Market, by End-User, 2023-2030 (USD Million)
Table 38 Europe: DNA Sequencing Market, by Region, 2023-2030 (USD Million)
Table 39 Western Europe: DNA Sequencing Market, by Types, 2023-2030 (USD Million)
Table 40 Western Europe: DNA Sequencing Market, by Product, 2023-2030 (USD Million)
Table 41 Western Europe: DNA Sequencing Market, by Technology, 2023-2030 (USD Million)
Table 42 Western Europe: DNA Sequencing Market, by Application, 2023-2030 (USD Million)
Table 43 Western Europe: DNA Sequencing Market, by End-User, 2023-2030 (USD Million)
Table 44 Western Europe: DNA Sequencing Market, by Region, 2023-2030 (USD Million)
Table 45 Eastern Europe: DNA Sequencing Market, by Types, 2023-2030 (USD Million)
Table 46 Eastern Europe: DNA Sequencing Market, by Product, 2023-2030 (USD Million)
Table 47 Eastern Europe: DNA Sequencing Market, by Technology, 2023-2030 (USD Million)
Table 48 Eastern Europe: DNA Sequencing Market, by Application, 2023-2030 (USD Million)
Table 49 Eastern Europe: DNA Sequencing Market, by End-User, 2023-2030 (USD Million)
Table 50 Eastern Europe: DNA Sequencing Market, by Region, 2023-2030 (USD Million)
Table 51 Asia-Pacific: DNA Sequencing Market, by Types, 2023-2030 (USD Million)
Table 52 Asia-Pacific: DNA Sequencing Market, by Product, 2023-2030 (USD Million)
Table 53 Asia-Pacific: DNA Sequencing Market, by Technology, 2023-2030 (USD Million)
Table 54 Asia-Pacific: DNA Sequencing Market, by Application, 2023-2030 (USD Million)
Table 55 Asia-Pacific: DNA Sequencing Market, by End-User, 2023-2030 (USD Million)
Table 56 Asia-Pacific: DNA Sequencing Market, by Region, 2023-2030 (USD Million)
Table 57 Middle East & Africa: DNA Sequencing Market, by Types, 2023-2030 (USD Million)
Table 58 Middle East & Africa: DNA Sequencing Market, by Product, 2023-2030 (USD Million)
Table 59 Middle East & Africa: DNA Sequencing Market, by Technology, 2023-2030 (USD Million)
Table 60 Middle East & Africa: DNA Sequencing Market, by Application, 2023-2030 (USD Million)
Table 61 Middle East & Africa: DNA Sequencing Market, by End-User, 2023-2030 (USD Million)
Table 62 Middle East & Africa: DNA Sequencing Market, by Region, 2023-2030 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global DNA Sequencing Market
Figure 3 Segmentation Market Dynamics for Global DNA Sequencing Market
Figure 4 Global DNA Sequencing Market Share, by Types, 2020 (%)
Figure 5 Global DNA Sequencing Market Share, by Product, 2020 (%)
Figure 6 Global DNA Sequencing Market Share, by Technology, 2020 (%)
Figure 7 Global DNA Sequencing Market Share, by Application, 2020 (%)
Figure 8 Global DNA Sequencing Market Share, by End-User, 2020 (%)
Figure 9 Global DNA Sequencing Market Share, by Region, 2020 (%)
Figure 10 North America: DNA Sequencing Market Share, by Country, 2020 (%)
Figure 11 Europe: DNA Sequencing Market Share, by Country, 2020 (%)
Figure 12 Asia-Pacific: DNA Sequencing Market Share, by Country, 2020 (%)
Figure 13 Middle East & Africa: DNA Sequencing Market Share, by Country, 2020 (%)
Figure 14 Global DNA Sequencing Market: Company Share Analysis, 2020 (%)
Figure 15 Perkin Elmer: Key Financials
Figure 16 Perkin Elmer: Segmental Revenue
Figure 17 Perkin Elmer: Geographical Revenue
Figure 18 Roche Holdings AG: Key Financials
Figure 19 Roche Holdings AG: Segmental Revenue
Figure 20 Roche Holdings AG: Geographical Revenue
Figure 21 Siemens AG: Key Financials
Figure 22 Siemens AG: Segmental Revenue
Figure 23 Siemens AG: Geographical Revenue
Figure 24 Illumina: Key Financials
Figure 25 Illumina: Segmental Revenue
Figure 26 Illumina: Geographical Revenue
Figure 27 Agilent Technologies Inc.: Key Financials
Figure 28 Agilent Technologies Inc.: Segmental Revenue
Figure 29 Agilent Technologies Inc.: Geographical Revenue
Figure 30 Genia corporation: Key Financials
Figure 31 Genia corporation: Segmental Revenue
Figure 32 Genia corporation: Geographical Revenue
Figure 33 Oxford Nanopore technologies: Key Financials
Figure 34 Oxford Nanopore technologies: Segmental Revenue
Figure 35 Oxford Nanopore technologies: Geographical Revenue
Figure 36 Koninklijke Philips N.V.: Key Financials
Figure 37 Koninklijke Philips N.V.: Segmental Revenue
Figure 38 Koninklijke Philips N.V.: Geographical Revenue
Figure 39 Pacific Biosciences: Key Financials
Figure 40 Pacific Biosciences: Segmental Revenue
Figure 41 Pacific Biosciences: Geographical Revenue
Figure 42 Johnson & Johnson: Key Financials
Figure 43 Johnson & Johnson: Segmental Revenue
Figure 44 Johnson & Johnson: Geographical Revenue
Figure 45 Deep Genomics, Inc.: Key Financials
Figure 46 Deep Genomics, Inc.: Segmental Revenue
Figure 47 Deep Genomics, Inc.: Geographical Revenue
Figure 48 Life Technologies: Key Financials
Figure 49 Life Technologies: Segmental Revenue
Figure 50 Life Technologies: Geographical Revenue
Figure 51 Eppendorf.: Key Financials
Figure 52 Eppendorf.: Segmental Revenue
Figure 53 Eppendorf.: Geographical Revenue
Figure 54 Tecan: Key Financials
Figure 55 Tecan: Segmental Revenue
Figure 56 Tecan: Geographical Revenue
Figure 57 Hamilton Thorne Biosciences: Key Financials
Figure 58 Hamilton Thorne Biosciences: Segmental Revenue
Figure 59 Hamilton Thorne Biosciences: Geographical Revenue
Figure 60 General Electric Company: Key Financials
Figure 61 General Electric Company: Segmental Revenue
Figure 62 General Electric Company: Geographical Revenue
Figure 63 Siemens Healthineers GmbH: Key Financials
Figure 64 Siemens Healthineers GmbH: Segmental Revenue
Figure 65 Siemens Healthineers GmbH: Geographical Revenue
Figure 66 Myriad Genetics: Key Financials
Figure 67 Myriad Genetics: Segmental Revenue
Figure 68 Myriad Genetics: Geographical Revenue
Figure 69 Beckman Coulter: Key Financials
Figure 70 Beckman Coulter: Segmental Revenue
Figure 71 Beckman Coulter: Geographical Revenue
Figure 72 Thermo Scientific: Key Financials
Figure 73 Thermo Scientific: Segmental Revenue
Figure 74 Thermo Scientific: Geographical Revenue
